By demonstrating the critical role of metformin dosage and hormonal factors, particularly hyperprolactinemia, in modulating galectin-3 levels, these findings challenge traditional paradigms focused solely on pharmacokinetics and pave the way for exploring galectin-3 as a novel therapeutic target in PCOS. This evidence concerns the gene LGALS3 and polycystic ovary syndrome.